A 28-year-old man presents with allergic rhinitis, primarily due to grass pollen, that has not previously responded to antihistamines and nasal sprays. A trial of sublingual immunotherapy is recommended. Sublingual immunotherapy is more convenient than injection immunotherapy. However, only one agent, which is specific for grass-pollen allergies, has been approved for clinical use in some European countries. The Food and Drug Administration has not approved any agent for sublingual immunotherapy.
No takes yet. Share an insight, caveat, or question.
Anthony J. Frew (2008) studied this question.